LLY Bulls and Bears Clash at $920–$940: Options Signal Volatility, Earnings Boost, and Buybacks Create High-Probability Setups

• Eli Lilly (LLY) is trading sideways with a short-term bearish bias, hovering near its 200D support at $918.70.
• Options market shows a call/put imbalance with heavy open interest at $940 and $890 strikes, hinting at a potential breakout or breakdown scenario.
• Strong Q4 earnings, buybacks, and a $1.8B acquisition suggest LLY is in a strategic growth phase, but a pricing inquiry introduces near-term regulatory risk.

Here's the core takeaway: The stock is stuck in a tight trading range, but options data and recent news suggest the market is bracing for a move—up or down. With a call/put ratio of 1.23 for open interest, bearish sentiment is currently dominant, but the news flow and buyback program could flip the script by week’s end.

What Options Market Sentiment Says About the Battle at $940 and $890

Looking at the OTM options activity, the largest open interest in calls for this Friday is at $1100 (2775 contracts) and $1200 (2222 contracts), while the top OTM puts are at $640 (3397) and $400 (3131). These strikes are far from the current price of $911.96, but the heavy open interest at these levels tells us that a few key players are either hedging against a dramatic move or speculating on a major catalyst.

The next Friday options show a similar pattern: calls at $1125 and $1220 are the top call OI, while puts are concentrated around $890 (1694 contracts) and $900 (1342). This suggests that the bearish sentiment is extending further into next week, but the call side isn't giving up either. It’s a sign that the market is expecting a move—just not sure in which direction.

The put/call ratio of 1.23 means that more capital is being bet on a downward move, at least for now. That could be smart positioning if you expect a sell-off from earnings optimism or regulatory worries. But don’t overlook the call-heavy activity at the $1100 strike—it’s not just noise; it’s a signal that someone out there is making a call (pun intended) for a rally into next week.

How LLY’s Earnings Beat, Buybacks, and M&A Fit Into This Narrative

Here’s where it gets interesting. LLY just posted a strong Q4 earnings beat, with revenue of $9.8B beating estimates by $600M and guidance for 5–7% growth in 2026. Analysts have raised price targets into the $600s, and the company is throwing in a $2B buyback and a major acquisition of Cerevel. That’s bullish stuff—so why are the options leaning bearish?

Maybe the market is pricing in short-term volatility from the HHS pricing inquiry, or perhaps the big move by institutional investors like BlackRock and Vanguard is already reflected in the price. Either way, the news supports a long-term bullish stance but doesn’t rule out a pullback or consolidation. The key is that the fundamentals are strong, but sentiment is mixed. That creates a trading opportunity.

Trade Ideas for LLY Today: Where to Enter and When to Exit

For those looking to trade this setup, here are a few specific strategies:

• Bull Call Spread (Short-Term): Buy the LLY20260327C940 for $18.50 and sell the LLY20260327C1030 for $10.00. This captures upside between $940 and $1030 with limited risk. The idea is that LLY has support at $917.50 and resistance at $920.32. If it holds and bounces off the 30D support, a push toward $940 is likely.

• Bears Play the Put at $890: Buy the LLY20260327P890 for $21.00. If LLY breaks below the $910.55 intraday low, this could be a low-risk short-term play. The RSI is at 17.75, suggesting it’s oversold, but the MACD is negative. A break below $910 could trigger more puts and a move to $890.

• Core Stock Positioning: For investors, consider a long entry if LLY holds above $917.50. Set a stop-loss at $910.55, and a first target at $935, which is the upper end of the Bollinger Band. A breakout above $925.37 (intraday high) would confirm the bulls are in control.

Volatility on the Horizon: What to Watch

LLY is at a crossroads. The fundamentals are strong—buybacks, M&A, and a solid R&D pipeline—but the options market is bracing for a swing. The key question is whether the bullish momentum from earnings can overcome the bearish sentiment reflected in the put-heavy OI.

With a major investor day scheduled for April 9 and an FDA fast-track decision for its Alzheimer’s drug, the next few weeks will be crucial. The stock could either break out toward $940 and beyond or face a test at $890 if bearish sentiment intensifies.

Bottom line: This is not a time to be passive. The options activity and news flow together create a high-probability setup. Whether you go long or short, the key is to define your risk and take a position before the market decides the direction. And if you do nothing, you might miss one of the stronger setups in 2026 so far.